世界の血液型検査試薬の市場規模は、予測期間中に7.74％の大幅なCAGRで堅調に拡大し、2027年までに26億4,217万ドルに達すると予想されます。血液型診断の数の増加と人口の増加によって、ロボット化された血液型分類装置への関心が高まっています。完全にロボット化された構造物は、単独の情報で多くの検査を実行することができ、特定のすう勢の中での有用性と習熟度をさらに拡大します。また、メーカーは、チェックと結果の承認をアップグレードするために、リモートアクセス機能を備えた完全にロボット化された血液組成装置を提供しています。 さらに、このハードウェアにはシリンダーサイズと測定確認の明確なハイライト、組み込まれた品質管理プログラム、試薬とテストステータスに関する継続的なデータ、高品質のシェーディング結果などの特徴があります。
世界の血液型検査試薬市場は、2020年に15億7,787万ドルに達したと推定されます。市場の成長を促す要因は、慢性疾患の発生率の上昇と医学研究への支出の増加です。一方で、検査キットの精度と有効性に関する懸念が市場の成長を阻んでいます。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISORDERS
4.2.2 INCREASING SPENDING IN MEDICAL RESEARCH
4.3 RESTRAINT
4.3.1 CONCERNS PERTAINING TO THE EFFICIENCY AND ACCURACY OF TEST KITS
4.4 OPPORTUNITY
4.4.1 EMERGENCE OF AUTOMATED BLOOD GROUPING DEVICES
4.5 TECHNOLOGICAL DISRUPTION
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES REVIEW
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF BUYERS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
5.4 VOLUME OF TESTS FOR DONATED BLOOD, BY REGION, 2020
5.5 BLOOD TRANSFUSION VOLUME, BY REGION, 2020
6 GLOBAL BLOOD GROUPING REAGENTS, BY PRODUCT
6.1 OVERVIEW
6.2 CONSUMABLES
6.3 INSTRUMENTS
6.3.1 FULLY-AUTOMATED INSTRUMENTS
6.3.2 SEMI-AUTOMATED INSTRUMENTS
7 GLOBAL BLOOD GROUPING REAGENTS, BY TECHNIQUE
7.1 OVERVIEW
7.2 PCR-BASED AND MICROARRAY TECHNIQUE
7.3 ASSAY-BASED TECHNIQUES
7.4 MASSIVELY PARALLEL SEQUENCING TECHNIQUES
7.5 SEROLOGY
7.5.1 GEL TECHNIQUE
7.5.2 EMT
7.5.3 SPRCA
7.5.4 GLASS SLIDE AND TUBES
7.5.5 CASSETTE/KIT
7.5.6 OTHER SEROLOGY
7.6 OTHER TECHNIQUES
8 GLOBAL BLOOD GROUPING REAGENTS, BY TEST TYPE
8.1 OVERVIEW
8.2 BLOOD GROUP AND PHENOTYPES
8.3 ANTIBODY SCREENING
8.4 CROSSMATCHING TESTS
8.5 ANTIBODY IDENTIFICATION
8.6 COOMBS TEST
8.7 ANTIGEN TYPING
9 GLOBAL BLOOD GROUPING REAGENTS, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 BLOOD BANKS
9.4 CLINICAL LABORATORIES
10 GLOBAL BLOOD GROUPING REAGENTS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 SPAIN
10.3.5 ITALY
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVE OVERVIEW
11.2 MAJOR PLAYERS IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.4 COMPETITIVE BENCHMARKING
11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
11.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
11.7 MAJOR PLAYERS FINANCIAL MATRIX
11.7.1 REVENUE OF MAJOR PLAYERS, 2020
11.7.2 R&D EXPENDITURE
12 COMPANY PROFILES
12.1 MERCK KGAA
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 BIO-RAD LABORATORIES, INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 NOVACYT GROUP
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 BECKMAN COULTER, INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 HAEMOKINESIS PTY LTD
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 MTC MED. PRODUKTE GMBH
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 DAY MEDICAL SA
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 RAPID LABS LTD
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 ORTHO CLINICAL DIAGNOSTICS
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 DIAGAST SAS
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 GRIFOLS SA
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
12.12 IMMUCOR, INC.
12.12.1 COMPANY OVERVIEW
12.12.2 FINANCIAL OVERVIEW
12.12.3 PRODUCTS/SERVICES OFFERED
12.12.4 KEY DEVELOPMENTS
12.12.5 SWOT ANALYSIS
12.12.6 KEY STRATEGIES
12.13 QUOTIENT LTD
12.13.1 COMPANY OVERVIEWS
12.13.2 FINANCIAL OVERVIEW
12.13.3 PRODUCTS/SERVICES OFFERED
12.13.4 KEY DEVELOPMENTS
12.13.5 SWOT ANALYSIS
12.13.6 KEY STRATEGIES
12.14 YUVRAJ BIOBIZ INCUBATOR INDIA PVT LTD
12.14.1 COMPANY OVERVIEW
12.14.2 FINANCIAL OVERVIEW
12.14.3 PRODUCTS/SERVICES OFFERED
12.14.4 KEY DEVELOPMENTS
12.14.5 KEY STRATEGIES
12.15 TULIP DIAGNOSTICS
12.15.1 COMPANY OVERVIEW
12.15.2 FINANCIAL OVERVIEW
12.15.3 PRODUCTS/SERVICES OFFERED
12.15.4 KEY DEVELOPMENTS
12.15.5 KEY STRATEGIES
12.16 AIKANG
12.16.1 COMPANY OVERVIEW
12.16.2 FINANCIAL OVERVIEW
12.16.3 PRODUCTS/SERVICES OFFERED
12.16.4 KEY DEVELOPMENTS
12.16.5 KEY STRATEGIES
12.17 INTEC
12.17.1 COMPANY OVERVIEW
12.17.2 FINANCIAL OVERVIEW
12.17.3 PRODUCTS OFFERED
12.17.4 KEY DEVELOPMENTS
12.17.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
